...
首页> 外文期刊>Journal of Hepatology: The Journal of the European Association for the Study of the Liver >Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production.
【24h】

Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production.

机译:吡非尼酮对大鼠肝星状细胞增殖和胶原生成的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND/AIMS: Pirfenidone has been recently shown to reduce dimethynitrosamine-induced liver fibrosis in the rat, but no information are available on the effect of this drug on cultured hepatic stellate cells (HSC). METHODS: HSC proliferation was evaluated by measuring bromodeoxyuridine incorporation; PDGF-receptor autophosphorylation, extracellular signal-regulated kinase (ERK1/2) and pp70(S6K) activation were evaluated by western blot; protein kinase C activation was evaluated by western blot and by ELISA; type I collagen accumulation and alpha1(I) procollagen mRNA expression were evaluated by ELISA and northern blot, respectively. RESULTS: Pirfenidone significantly inhibited PDGF-induced HSC proliferation, starting at a concentration of 1 microM, with a maximal effect at 1000 microM, without affecting HSC viability and without inducing apoptosis. The inhibition of PDGF-induced HSC proliferation was associated neither with variations in PDGF-receptor autophosphorylation, or with ERK1/2 and pp70(S6K) activation. On the other hand, pirfenidone was able to inhibit PDGF-induced activation of the Na(+)/H(+) exchanger, which is involved in PDGF-induced HSC proliferation in HSC, with a maximal effect at 1000 microM and inhibited PDGF-induced protein kinase C activation. Pirfenidone 100 and 1000 microM inhibited type I collagen accumulation in the culture medium induced by transforming growth factor(beta1) by 54% and 92%, respectively, as well as TGF(beta1)-induced alpha1(I) procollagen mRNA expression. RESULTS: Pirfenidone could be a new candidate for antifibrotic therapy in chronic liver diseases.
机译:背景/目的:吡非尼酮最近已显示可减轻大鼠中二甲基亚硝胺诱导的肝纤维化,但尚无有关该药物对培养的肝星状细胞(HSC)作用的信息。方法:通过测量溴脱氧尿苷掺入量评估HSC的增殖; Western blot检测PDGF-受体自身磷酸化,细胞外信号调节激酶(ERK1 / 2)和pp70(S6K)的活化。通过蛋白质印迹和ELISA评估蛋白激酶C的激活;通过ELISA和Northern blot分别评估了I型胶原蛋白的积累和alpha1(I)前胶原mRNA的表达。结果:吡非尼酮以1 microM的浓度开始显着抑制PDGF诱导的HSC增殖,以1000 microM的浓度发挥最大作用,而不会影响HSC的生存能力且不诱导细胞凋亡。 PDGF诱导的HSC增殖的抑制与PDGF受体自身磷酸化的变化或ERK1 / 2和pp70(S6K)活化均无关。另一方面,吡非尼酮能够抑制PDGF诱导的Na(+)/ H(+)交换子的活化,这与PDGF诱导的HSC在HSC中的增殖有关,在1000 microM时发挥最大作用,并抑制PDGF-诱导蛋白激酶C活化。吡非尼酮100和1000 microM将转化生长因子β1诱导的培养基中的I型胶原蓄积分别抑制了54%和92%,以及TGFβ1诱导的alpha1(I)前胶原mRNA表达。结果:吡非尼酮可能成为慢性肝病抗纤维化治疗的新候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号